ASCO 2026 Preview: Late-Breaking Abstracts Poised to Reshape the Treatment Landscape

Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology, previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA-mutant metastatic breast cancer to BREAKWATER's first look at overall survival in BRAF V600E-mutant colorectal cancer, this episode breaks down the science, the clinical context, and the questions that full data will need to answer.